The results of our trial showed that Lido and Dex could preserve more NK cells, enhance IFN-γ status, and increase IL-2 levels postoperatively, which was strongly associated with better survival of NSCLC patients (41). Here, IL2 is linked to non-small cell lung carcinoma.